November 14, 2012

FDA approves Pfizer's rheumatoid arthritis treatment

FDA approves Pfizer's rheumatoid arthritis treatment
FDA approves Pfizer's rheumatoid arthritis treatment
Federal regulators recently approved Pfizer's new Xeljanz treatment for rheumatoid arthritis. Xeljanz was approved for patients with moderate to severe rheumatoid arthritis who did not benefit from the oral treatment methotrexate. Xeljanz can be used with methotrexate and certain other treatments. Industry analysts have predicted the new drug, also known as tofacitinib, could grow to sales of $3 billion annually. Xeljanz is taken in 5-milligram pills twice daily.  About 1.3 million people in the United States suffer from rheumatoid arthritis, which can cause problems in wound healing.
Similar Articles
Related Topics

More in Products

HealthLease purchase completed

CFG Capital Markets, the investment banking platform of Capital Funding Group, announced it was an advisor on a $141.7 million portfolio.

Bulk TV & Internet announce partnership

Bulk TV & Internet has become an authorized partner of Mitel, a provider of cloud and premises-based unified communications and collaboration software.

Oak Grove Capital closes line for Brookdale

Oak Grove Capital announced it has closed a $259 Fannie Mae DUS credit facility for Brookdale Senior Living.